Skip to content

Content Library

Exclusive Speaker Interview: Matt Cooper

Matt Cooper
Chief Executive Officer & Co-Founder
Inflammasome Therapeutics Summit speaker faculty


What do you believe to be the biggest challenges that inflammasome developers are currently facing?

Proof of concept in the appropriate clinical indication(s). There are thousands of scientific papers describing animal model efficacy and target validation for inflammasomes. Together, they implicate a putative causal role for inflammasome activation in disease, but it is not known if these findings will translate to humans. Although blocking IL-1β has been validated in some human diseases, inhibiting NLRP3 may be different as it will also suppress downstream IL-18 and pyroptosis (lytic cell death) while leaving the biological activity of other inflammasome members intact to fight infection...